Omega-3 fatty acid improves the clinical outcome of hepatectomized patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma

Zhengshan Wu\textsuperscript{a,b}, Jianjie Qin\textsuperscript{a,b}, Liyong Pu\textsuperscript{a,b,*}

\textsuperscript{a}Liver Transplantation Center, the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, China; \textsuperscript{b}Key Laboratory of Living Donor Liver Transplantation, Ministry of Public Health, Nanjing, Jiangsu 210029, China.

Received 31 May 2012, Revised 25 July 2012, Accepted 5 October 2012, Epub 23 October 2012

Abstract

Omega-3 fatty acid supplemented total parenteral nutrition improves the clinical outcome of patients undergoing certain operations; however, its benefits for patients with hepatitis type B virus (HBV)-associated hepatocellular carcinoma (HCC) who have undergone hepatectomy are still not clear. The aim of this study was to evaluate the effect of omega-3 fatty acid supplemented total parenteral nutrition on the clinical outcome of patients with HBV-associated HCC who underwent hepatectomy at our institution. A total of 63 patients with HBV-associated HCC who underwent hepatectomy were included in this study. These patients were randomly assigned to receive standard total parenteral nutrition (the control group, \(n = 31\)) or omega-3 fatty acid supplemented total parenteral nutrition (the omega-3 fatty acid group, \(n = 32\)) for at least 5 d. The study endpoints were the occurrence of infection-related complications, recovery of liver function and length of hospital stay. The results showed that the omega-3 fatty acid group had a lower infection rate (omega-3 fatty acid, 19.4\% vs control, 43.8\%, \(P < 0.05\)), a better liver function after hepatectomy: alanine transaminase (omega-3 fatty acid, 48.23 ± 18.48 U/L vs control, 73.34 ± 40.60 U/L, \(P < 0.01\)), aspartate transaminase (omega-3 fatty acid, 35.77 ± 14.56 U/L vs control, 50.53 ± 24.62 U/L, \(P < 0.01\)), total bilirubin (omega-3 fatty acid, 24.29 ± 7.40 mmol/L vs control, 28.37 ± 8.06 mmol/L, \(P < 0.05\)) and a shorter length of hospital stay (omega-3 fatty acid, 12.71 ± 2.58 d vs control, 15.91 ± 3.23 d, \(P < 0.01\)). The serum contents of IL-6 (omega-3 fatty acid, 23.98 ± 5.63 pg/mL vs control, 35.55 ± 7.5 pg/mL, \(P < 0.01\)) and TNF-\(\alpha\) (omega-3 fatty acid, 4.43 ± 1.22 pg/mL vs control, 5.96 ± 1.58 pg/mL, \(P < 0.01\)) after hepatectomy were significantly lower in the omega-3 fatty acid group than those of the control group. In conclusion, administration of omega-3 fatty acid may reduce infection rate and improve liver function recovery in HBV-associated HCC patients after hepatectomy. This improvement is associated with suppressed production of proinflammatory cytokines in these patients.

Keywords: omega-3 fatty acids, hepatectomy, total parenteral nutrition, hepatocellular carcinoma
INTRODUCTION

Lipids are key energy sources in critically ill patients due to their high energy density, low osmolarity, and preferred utilization during the systemic inflammatory response. Benefits of omega-3 fatty acids have been observed in humans and in animal models of diabetes, obesity, cancer, and cardiovascular diseases. Thus, it is important to promote the consumption of omega-3 fatty acids.

Recent studies have indicated that omega-3 fatty acids are safe for cancer patients and play a very important role for patients who need total parenteral nutrition (TPN). Using a high-dose short-term infusion of omega-3 fatty acid lipid emulsion may cause rapid immunologic changes, through which the effects on the endotoxin-induced stress response may be achieved. In this randomized controlled study, we evaluated the effect of omega-3 fatty acid supplemented TPN on the clinical outcomes of patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) after hepatectomy.

SUBJECTS AND METHODS

Patients

In this prospective, randomized, controlled single center study, 69 consecutive patients with liver cancer undergoing hepatectomy were prospectively enrolled from January 2007 and December 2008. All the enrolled patients underwent hepatectomy due to HCC. The inclusion criteria were preoperative liver function of Child-Pugh A and serum HBV-DNA less than 1,000 copies/L. Eligible patients underwent hepatectomy were assigned to receive TPN for at least 5 d with or without omegat-3 fatty acid supplement. Six patients were excluded from the study because they received TPN for less than 5 d. The major exclusion criteria were severe hemorrhage, unstable diabetes mellitus, persistent hemodynamic failure (systolic blood pressure <90 mmHg), and allergic reactions to fish or egg proteins. There were no remarkable differences between the two groups in gender, ages, diagnosis, warm ischemia time, body mass index, liver function, blood loss and duration of surgery (Table 1).

The study protocol was approved by the local institutional review board at the authors’ affiliated institutions and informed consent was obtained from each subject or his or her legal surrogates.

Interventions

Patients were randomized by computer-derived block randomization. The pharmacist was the only person who was aware of the randomization list. Both the patients and the investigators were unaware of the infused drug. All the patients received TPN consisting of amino acids, glucose, a soybean oil emulsion or an omega-3 lipid emulsion supplement (Omegaven, Fresenius-Kabi; Omegaven is comprised 10% pure omega-3 fatty acids,) for longer than 5 d via a central venous catheter. The TPN emulsion was freshly prepared in the hospital pharmacy and labeled with patient and study numbers, the name of the investigator, and the date of the preparation. Omega-3 fatty acids were added to standard TPN. Both groups of patients received isonitrogenous (0.24 g/kg·d) and isocaloric (35 kcal/k·d) regimens supplied as constant intravenous infusion via central veins. The supply was administered for 5 to 7 d (the control group, 5.8±0.6 d; the omega-3 fatty acid group, 5.6±0.4 d) as clinically indicated, as follows: 1.5 g/kg·d of amino acids (Novamin), 3.5 g/kg·d of glucose, 1.5 g/kg·d of lipid emulsion (Lipovenos or Omegaven). Standard vitamins (Solvit), electrolytes and trace elements (Addamel) were supplied according to the protocol of our hospital. Insulin therapy was started according to the level of blood glucose when indicated (glucose:insulin 4:1).

Laboratory studies

The parameters alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBIL), and albumin (ALB) were quantified by the Department of Clinical Chemistry, the First Affiliated Hospital of Nanjing Medical University (Nanjing, China) accord-

Table 1 Characteristics of patients in the study

| Characteristics                | Omega-3 fatty acid group (n = 31) | Control group (n = 32) | P     |
|-------------------------------|----------------------------------|-----------------------|-------|
| Gender (male/female)          | 25/6                             | 25/7                  | 0.806 |
| Age (years)                   | 52.00±7.90                       | 52.16±8.31            | 0.939 |
| Body mass index (BMI)         | 22.47±1.80                       | 22.64±1.63            | 0.702 |
| Duration of operation (h)     | 3.57±0.98                        | 3.64±0.93             | 0.754 |
| Warm ischemia time (min)      | 11.52±4.86                       | 11.56±4.09            | 0.967 |
| Blood loss (mL)               | 344±146                          | 341±137               | 0.942 |
| Volume of resection (mL)      | 179±106                          | 187±125               | 0.786 |
Omega-3 fatty acid improves outcome of hepatectomized patients

TG.1.3 fatty acid improves outcome of hepatectomized patients

The calculation was based on the results of the previous clinical trial available at the time when the trial was designed. The calculated sample size reached the number of 63 evaluable patients. To take into account some dropouts, the trial was planned initially to include 70 patients. Patients with less than 5 d of TPN were not eligible for efficacy evaluation. Finally, 63 patients were included. Statistical analysis was performed by SPSS (Version 16.0, Chicago, IL, China). Quantitative data were presented as arithmetic mean ± SD. Quantitative variance was analyzed by Student’s t-test and qualitative variance was analyzed by chi-square test. P < 0.05 was considered statistically significant.

RESULTS

Patients receiving omega-3 fatty acid in TPN after hepatectomy had a lower nosocomial infection rate

Patients receiving omega-3 fatty acid had a significantly lower nosocomial infection rate (omega-3 fatty acid, 6/31, 19.4% vs control, 14/32, 43.8%, P < 0.05) (Table 2). The decrease in nosocomial infections in patients receiving omega-3 fatty acid was mainly due to reduced incidence of pneumonia (omega-3 fatty acid, 4/32, 12.5% vs control, 11/31, 35.48%, respectively). The overall incidence of other infections (surgical wound, urinary or intravenous catheter infection) was similar in the omega-3 fatty acid and control group with an average of 2 and 3 episodes.

The six-month outcome was evaluated for all patients through reviewing hospital charts or contacting the practitioners. The length of hospital stay (omega-3 fatty acid, 12.71 ± 2.58 d vs control, 15.91 ± 3.23 d, P < 0.01) (Table 2) was shorter in the omega-3 fatty acid group than the control group. The six-month mortality was not different between the two groups (Table 2).

Patients receiving omega-3 fatty acid in TPN after hepatectomy had a faster recovery of liver function

The liver function tests were significantly different between the two groups after hepatectomy on postoperative d 6: ALT (omega-3 fatty acid, 48.23 ± 18.48 U/L vs control, 73.34 ± 40.60 U/L, P < 0.01), AST (omega-3 fatty acid, 35.77 ± 14.56 U/L vs control, 50.53 ± 24.62 U/L, P < 0.01), TBIL (omega-3 fatty acid, 24.29 ± 7.40 mmol/L vs control, 28.37 ± 8.06 mmol/L, P < 0.05) (Table 3). But there was no difference between the two groups in plasma albumin concentrations (omega-3 fatty acid, 39.84 ± 3.87 g/L vs 38.69 ± 3.91 g/L, P = 0.245) (Table 3).

Table 2 Clinical outcomes of the patients in the study

| Variables                | Omega-3 fatty acid group (n = 31) | Control group (n = 32) | P     |
|--------------------------|-----------------------------------|------------------------|-------|
| Nosocomial infections    | 6                                 | 14                     | <0.05 |
| LOS (d)                  | 12.71 ±2.58                       | 15.91 ±3.23            | <0.01 |
| Mortality (6 months)     | 0                                 | 0                      | >0.05 |

LOS: the length of hospital stay.

Table 3 Liver functions of patients in the study

| Variables | Omega-3 fatty acid group (n = 31) | Control group (n = 32) | P    |
|-----------|-----------------------------------|------------------------|------|
| Pre-operation: |                                  |                        |      |
| ALT       | 28.39 ± 14.84                     | 29.22 ± 17.22          | 0.838|
| AST       | 25.84 ± 13.04                     | 25.69 ± 13.24          | 0.964|
| TBIL      | 17.58 ± 4.96                      | 16.81 ± 4.45           | 0.520|
| ALB       | 40.48 ± 4.25                      | 40.44 ± 3.78           | 0.964|
| POD 6:    |                                   |                        |      |
| ALT       | 48.23 ± 18.48                     | 73.34 ± 40.60          | <0.010|
| AST       | 35.77 ± 14.56                     | 50.53 ± 24.62          | <0.010|
| TBIL      | 24.29 ± 7.40                      | 28.37 ± 8.06           | <0.050|
| ALB       | 39.84 ± 3.87                      | 38.69 ± 3.91           | 0.245|

ALB: albumin; ALT: alanine transaminase; AST: aspartate transaminase; TBIL: total bilirubin.
Patients receiving omega-3 fatty acid in TPN after hepatectomy had lower serum levels of proinflammatory cytokines

Because IL-6 and TNF-α are associated with acute inflammation, we measured the serum contents of IL-6 and TNF-α in the two groups. Although there were no differences in the two groups before hepatectomy, serum IL-6 content (omega-3 fatty acid, 23.98±5.63 pg/mL vs 35.55±7.5 pg/mL, P < 0.01) and TNF-α content (omega-3 fatty acid, 4.43±1.22 pg/mL vs 5.96±1.58 pg/mL, P < 0.01) in the omega-3 fatty acid group after hepatectomy on postoperative day 6 were significantly lower than the control group (Table 4).

**DISCUSSION**

In addition to caloric support, lipid emulsions have the capacity to modify the immune response. Omega-3 fatty acids are recognized for their ability to modify leukocyte activity, alter lipid mediator generation, and to modulate cytokine release.[11] A recent meta-analysis showed that use of Omega-3 fatty acid lipid emulsions which are rich in omega-3 fatty acids may reduce ventilation time, mortality, antibiotic demand, and length of hospital stay in surgical patients.[12] Omega-3 fatty acids contained in fish oil have beneficial properties of reduction of inflammatory reaction and immunological modulation.[13]

In this single center, prospective, double-blind trial, omega-3 fatty acid-supplemented TPN improves the clinical outcome after hepatectomy. The two groups have similar demographic and baseline characteristics at inclusion. The complication rate in the control group is higher than that of the treatment group, which is consistent with previously published results.[14,15] Omega-3 fatty acid-treated liver cancer patients clearly benefit from omega-3 fatty acid supplementation.[16]

In the present study, omega-3 fatty acid-supplemented TPN was associated with a lower incidence of infectious events. The result is in accordance with previous study revealing the reduction of infectious events observed after administration of omega-3 fatty acid enteral nutrition to trauma patient.[17] This study suggests that omega-3 fatty acid-enriched nutrition reduces infectious complications in patients after hepatectomy.

The reduction of infectious complications is mainly due to a lower incidence of pneumonia as previously reported with the use of omega-3 fatty acid-enriched enteral nutrition.[18] Mechanisms accounting for these effects are reduced levels of PGE2 and inducible NO synthase as well as an increased lipid peroxidation. Furthermore, omega-3 fatty acid is capable of down-regulating the production of a number of mediators such as IL-1, IL-6, TNF-α and proteolysis-inducing factor.[19,20] In our study, serum IL-6 and TNF-α levels in the omega-3 fatty acid group after hepatectomy on postoperative day 6 were significantly lower than the control group, revealing that omega-3 fatty acids may suppress the proinflammatory cytokines after hepatectomy.

In contrast to previous reports,[20] there was no difference in mortality between two groups during hospital stay and the 6-month follow up. However, the short period of follow up in this study may be the culprit. In the study, we find that the length of hospital stay was shorter in the omega-3 fatty acid group than that of the control group, which is due to the reduction of infection, especially the reduction of pneumonia and increased rate of recovery of liver function.

Omega-3 fatty acid supplementation ameliorates liver function after hepatectomy in the present study. The recovery of liver function is significantly faster in the omega-3 fatty acid group than the control group, which is consistent with previous study in animal model.[21] ALT, AST, and TBIL recovered rapidly in the omega-3 fatty acid group, but no difference was observed in plasma albumin levels. However, all the patients received albumin infusion routinely after hepatectomy to keep plasma albumin higher than 30 g/L as our protocol. The improvement of clinical outcome could be explained by the influence of omega-3 fatty acid on immune function especially through suppressing the production of proinflammatory cytokines such as IL-6 and TNF-α.

---

**Table 4** Serum IL-6 and TNF-α of the patients in the study

| Variables   | Omega-3 fatty acid group (n = 31) | Control group (n = 32) | P       |
|-------------|-----------------------------------|------------------------|---------|
| Pre-operation: |                                   |                        |         |
| IL-6        | 13.45±3.21                        | 13.04±3.83             | 0.647   |
| TNF-α       | 3.69±1.41                         | 3.72±1.37              | 0.935   |
| POD 6:      |                                   |                        |         |
| IL-6        | 23.98±5.63                        | 35.55±7.5              | < 0.010 |
| TNF-α       | 4.43±1.22                         | 5.96±1.58              | < 0.010 |

POD: post operation day; IL-6: interleukin-6; TNF-α: tumor necrosis factor-α. 
In conclusion, omega-3 fatty acid–supplemented TPN reduces the occurrence of infection mainly through a reduced incidence of pneumonia and increases the recovery rate of liver function after hepatectomy. Clearly, this will benefit patients after hepatectomy. These findings will provide a strong rationale for the use of omega-3 fatty acid-supplemented regimens in clinical practice.

References

[1] Caramia G. Omega-3: from cod-liver oil to nutrigenomics. *Minerva Pediatr* 2008; 60: 443-55.

[2] Rodríguez-Cruz M, Tovar AR, del Prado M, Torres N. Molecular mechanisms of action and health benefits of polyunsaturated fatty acids. *Rev Invest Clin* 2005; 57: 457-72.

[3] Oz HS, Chen TS, Neuman M. Nutrition intervention: a strategy against systemic inflammatory syndrome. *EN J Parenteral Enteral Nutr* 2009; 33: 380-9.

[4] Kishino T, Tanno M, Yamada H, Saito S, Matsumoto S. Changes in liver fatty acid unsaturation after partial hepatectomy in the rat. *Lipids* 2000; 35: 445-52.

[5] Calviello G, Palozza P, Franceschelli P, Frattucci A, Piccioni E, Tessitore L, et al. Eicosapentaenoic acid inhibits the growth of liver preneoplastic lesions and alters membrane phospholipid composition and peroxisomal beta-oxidation. *Nutr Cancer* 1999; 34: 206-12.

[6] Takasu S, Tsukamoto T, Hirata A, Kawai K, Toyoda T, Ban H, et al. Lack of initiation activity of 4-oxo-2-hexenal, a peroxidation product generated from omega-3 polyunsaturated fatty acids, in an in vivo five-week liver assay. *Asian Pac J Cancer Prev* 2007; 8: 372-4.

[7] Araseki M, Kobayashi H, Hosokawa M, Miyashita K. Lipid peroxidation of a human hepatoma cell line (HepG2) after incorporation of linoleic acid, arachidonic acid, and docosahexaenoic acid. *Biosci Biotechnol Biochem* 2005; 69: 483-90.

[8] Diamond IR, Pencharz PB, Wales PW. What is the current role for parenteral lipid emulsions containing omega-3 fatty acids in infants with short bowel syndrome? *Minerva Pediatr* 2009; 61: 263-72.

[9] Buckley JD, Howe PR. Anti-obesity effects of long-chain omega-3 polyunsaturated fatty acids. *Obes Rev* 2009; 10: 648-59.

[10] Oz HS, Chen TS, Neuman M. Nutrition intervention: a strategy against systemic inflammatory syndrome. *EN J Parenteral Enteral Nutr* 2009; 33: 380-9.

[11] Abel S, De Kock M, Smuts CM, Swanevelder S, Gelderblom WC. Dietary modulation of fatty acid profiles and oxidative status of rat hepatocyte nodules: effect of different n-6/n-3 fatty acid ratios. *Lipids* 2004; 39: 963-76.

[12] Senkal M, Haaker R, Linseisen J, Wolfram G, Homann HH, Stehle P. Preoperative oral supplementation with long-chain Omega-3 fatty acids beneficially alters phospholipid fatty acid patterns in liver, gut mucosa, and tumor tissue. *JPEN J Parenter Enteral Nutr* 2005; 29: 236-40.

[13] Rodríguez-Cruz M, Tovar AR, del Prado M, Torres N. Molecular mechanisms of action and health benefits of polyunsaturated fatty acids. *Rev Invest Clin* 2005; 57: 457-72.

[14] Barber MD, Preston T, McMillan DC, Slater C, Ross JA, Fearon KC. Modulation of the liver export protein synthetic response to feeding by an n-3 fatty-acid-enriched nutritional supplement is associated with anabolism in cachectic cancer patients. *Clin Sci* 2004; 106: 359-64.

[15] Heller AR, Rössel T, Gottschlich B, Tiebel O, Menschikowski M, Litz RJ, et al. Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients. *Int J Cancer* 2004; 114: 611-6.

[16] Stehr SN, Heller AR. Omega-3 fatty acid effects on biochemical indices following cancer surgery. *Clin Chim Acta* 2006; 373: 1-8.

[17] Chuntrasakul C, Siltham S, Sarasombath S, Sittapairochana C, Leowattana W, Chockvivatanavanit S, et al. Comparison of a immunonutrition formula enriched with arginine, glutamine and omega-3 fatty acid, with a currently high-enriched enteral nutrition for trauma patients. *J Med Assoc Thai* 2003; 86: 552-61.

[18] Merchant AT, Curhan GC, Rimm EB, Willett WC, Fawzi WW. Intake of n-6 and n-3 fatty acids and fish and risk of community-acquired pneumonia in US men. *Am J Clin Nutr* 2005; 82: 668-74.

[19] El-Badry AM, Graf R, Clavien PA. Omega 3 Ω Omega 6: What is right for the liver. *J Hepatol* 2007; 47: 718-25.

[20] Mayer K, Schaefer MB, Seeger W. Omega-3 fatty acid in the critically ill: from experimental to clinical data. *Curr Opin Clin Nutr Metab Care* 2006; 9: 140-8.

[21] Marsman HA, Heger M, Kloek JJ, Nienhuis SL, ten Kate FJ, van Gulik TM. Omega-3 fatty acids reduce hepatic steatosis and consequently attenuate ischemia-reperfusion injury following partial hepatectomy in rats. *Dig Liver Dis* 2011; 43: 984-90.